Top Story

First-line treatment for metastatic renal cell carcinoma evolving, but biomarkers still lacking

March 22, 2019
Meeting News

Rising PSA contributes to lack of clarity in nonmetastatic prostate cancer

March 22, 2019
NEW YORK — PSA is an “imperfect biomarker” that should inform prostate cancer treatment but not dictate it, according to a presenter at HemOnc Today…

Molecular therapy for lung cancer has not evolved quickly enough

March 22, 2019
Molecular therapy for the treatment of lung cancer has not evolved enough to adequately extend survival of patients, according to a presenter at HemOnc Today New York…

Immunotherapy likely to become standard for recurrent/metastatic head and neck cancers

March 22, 2019
The standard treatment for patients with recurrent or metastatic head and neck cancers is expected to change from chemotherapy to immunotherapy based on results of…
In the Journals

Machine-learning algorithms may identify those at risk for opioid overdose

March 22, 2019
Researchers have found machine-learning algorithms that appear to accurately identify people at risk for opioid overdose, according to findings recently published in…
More Headlines »

Ace the Case: A 72-Year-Old Man With Fatigue, Weight Loss, and Lymphocytosis

There is no commercial support for this activity.

This educational activity will review the diagnosis and management of a 72-year-old man with complaints of increasing…
More »
Meeting News

VIDEO: Trials explore optimal treatments, resistance in chronic lymphocytic leukemia

January 18, 2019
More »
Resource Centers
HemOnc Today New York

HemOnc Today New York


Sickle Cell Disease Forum: Innovation in Drug Development and Emerging Science

This activity is supported by an educational grant from Global Blood Therapeutics.

Sickle cell disease (SCD) is an inherited molecular condition whose clinical severity has extreme phenotypic…
More »
Current Issues
View the Current Issue
HemOnc Today Cell Therapy Next